Skip to main content
Premium Trial:

Request an Annual Quote

NextGen Developing Biomarker Assays for Takeda

Premium

This story originally ran on Feb. 3.

Biomarker firm NextGen Sciences this week announced it has entered into an agreement with Takeda Pharmaceutical to develop validated protein biomarker assays.

Terms of the agreement were not disclosed.

The assays will be used by Takeda in preclinical and clinical studies "to support their drive toward personalized medicine," NextGen said in a statement. The company added that the assays will be designed to target specific protein isoforms found in liver and muscle in multiple species. NextGen's multiple-reaction monitoring platform will be used.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.